BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37256648)

  • 1. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors.
    Sousa LG; McGrail DJ; Lazar Neto F; Li K; Marques-Piubelli ML; Ferri-Borgogno S; Dai H; Mitani Y; Spardy Burr N; Cooper ZA; Kinneer K; Cortez MA; Lin SY; Bell D; El Naggar A; Burks J; Ferrarotto R
    Clin Cancer Res; 2023 Aug; 29(16):3162-3171. PubMed ID: 37256648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma-Specific Prognostic Relevance.
    Siqueira JM; Mitani Y; Hoff CO; Bonini F; Guimaraes de Sousa L; Marques-Piubelli ML; Purushothaman A; Mitani M; Dai H; Lin SY; Spiotto MT; Hanna EY; McGrail DJ; El-Naggar AK; Ferrarotto R
    Mod Pathol; 2024 Jan; 37(1):100371. PubMed ID: 38015043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
    Hanna GJ; Grover P; Elliott A; McGrath J; Xiu J; Sukari A; Johnson JM; Wise-Draper T
    Clin Cancer Res; 2024 May; 30(10):2225-2232. PubMed ID: 38416410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.
    Ferrarotto R; Mitani Y; McGrail DJ; Li K; Karpinets TV; Bell D; Frank SJ; Song X; Kupferman ME; Liu B; Lee JJ; Glisson BS; Zhang J; Aster JC; Lin SY; Futreal PA; Heymach JV; El-Naggar AK
    Clin Cancer Res; 2021 Feb; 27(3):852-864. PubMed ID: 33172898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication.
    Dou S; Li R; He N; Zhang M; Jiang W; Ye L; Yang Y; Zhao G; Yang Y; Li J; Chen D; Zhu G
    Front Immunol; 2021; 12():618367. PubMed ID: 34552580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
    Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
    J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
    Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.
    Kinneer K; Wortmann P; Cooper ZA; Dickinson NJ; Masterson L; Cailleau T; Hutchinson I; Vijayakrishnan B; McFarlane M; Ball K; Davies M; Lewis A; Huang Y; Rosenbaum AI; Yuan J; Chesebrough J; Anderton J; Monks N; Novick S; Wang J; Dimasi N; Christie RJ; Sabol D; Tosto FA; Wallez Y; Leo E; Albertella MR; Staniszewska AD; Tice DA; Howard PW; Luheshi N; Sapra P
    Clin Cancer Res; 2023 Mar; 29(6):1086-1101. PubMed ID: 36355054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of B7-H4 is associated with infiltrating immune cells and poor prognosis in metastatic colorectal cancer.
    Ding S; Lv X; Liu Z; Zhan S; Xu Y; Zhang X; Liu C; Cao L
    Int Immunopharmacol; 2021 Jan; 90():107144. PubMed ID: 33187907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
    Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
    Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
    [No Abstract]   [Full Text] [Related]  

  • 11. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
    Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
    Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-deficiency of B7-H3 and B7-H4 identifies high CD8 + T cell infiltration and better prognosis in pancreatic cancer.
    Si S; Wang L; Cao H; Xu Y; Zhan Q
    BMC Cancer; 2022 Feb; 22(1):211. PubMed ID: 35219310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal B7-H4 from irradiated glioblastoma cells contributes to increase FoxP3 expression of differentiating Th1 cells and promotes tumor growth.
    Tian Y; Liu C; Li Z; Ai M; Wang B; Du K; Liu W; Wang H; Yu P; Chen C; Lin J; Xu A; Li R; Zhang W; Yuan Y
    Redox Biol; 2022 Oct; 56():102454. PubMed ID: 36044789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
    MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
    J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma.
    Hwang C; Lee HJ; Na JY; Kim KH; Song YJ; Kim JY; Kim K; Shin DH; Park JY; Kim SY; Lee JH; Choi KU
    J Ovarian Res; 2023 Jan; 16(1):3. PubMed ID: 36609273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma.
    Capone E; Perrotti V; Cela I; Lattanzio R; Togni L; Rubini C; Caponio VCA; Lo Muzio L; Colasante M; Giansanti F; Ippoliti R; Iacobelli S; Wick MJ; Spardy Burr N; Sala G
    Oral Oncol; 2024 Jan; 148():106635. PubMed ID: 37988837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H4 is a prognostic biomarker for poor survival in patients with pancreatic cancer.
    Shen L; Qian Y; Wu W; Weng T; Wang FXC; Hong B; Wu Z; Wang Q; Sang Y; Zhang H; Zhou X; Yao H
    Hum Pathol; 2017 Aug; 66():79-85. PubMed ID: 28600225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-H4 expression indicates poor prognosis of oral squamous cell carcinoma.
    Wu L; Deng WW; Yu GT; Mao L; Bu LL; Ma SR; Liu B; Zhang WF; Sun ZJ
    Cancer Immunol Immunother; 2016 Sep; 65(9):1035-45. PubMed ID: 27383830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-cell RNA sequencing reveals the heterogeneity and microenvironment in one adenoid cystic carcinoma sample.
    An PG; Wu WJ; Tang YF; Zhang J
    Funct Integr Genomics; 2023 May; 23(2):155. PubMed ID: 37162576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.